Ionis Pharmaceuticals (IONS) said late Thursday the US Food and Drug Administration has approved Tryngolza as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome.

The syndrome is genetic form of severe hypertriglyceridemia that can result in potentially life-threatening conditions, the company said.

The drug, also called olezarsen, was approved based on data from a phase 3 clinical trial in which it reduced triglyceride levels 42.5% from baseline to six months, the company said.

Shares of the company were up 7.5% in Friday's premarket activity.